Sunitinib Malate Market Forecast for Pancreatic Cancer, 2016-2021, G7 Countries, (U.S., Germany, France, U.K., Italy, Spain, Japan
|出版日期||內容資訊||英文 26 Pages
|G7各國的胰臟癌治療用Sunitinib蘋果酸市場 2020年∼2021年的預測 Sunitinib Malate Market Forecast for Pancreatic Cancer, 2016-2021, G7 Countries, (U.S., Germany, France, U.K., Italy, Spain, Japan|
|出版日期: 2016年05月19日||內容資訊: 英文 26 Pages||
本報告提供美國、德國、法國、英國、義大利、西班牙、日本的胰臟癌治療用Sunitinib蘋果酸 (Sutent) 市場相關調查分析，對各國的胰臟癌的發病率，5年存活率，患者數等資訊，為您概述為以下內容。
The sunitinib malate market for pancreatic cancer is projected to reach USD 76.7 million by 2021, at a CAGR of 13.9% from 2016 to 2021. The growing incidence of pancreatic cancer (especially pNET) and increasing adoption of sunitinib malate in patients with unrespectable, locally advanced, or metastatic pNET are the major factors driving the sunitinib malate market for pancreatic cancer in G7 Countries. The overall sunitinib malate market for pancreatic cancer in G7 countries is expected to witness double-digit growth in the coming years.
This report covers the sunitinib malate market for pancreatic cancer in G7 countries-U.S., Germany, France, U.K., Italy, Spain, and Japan. The U.S. is expected to be the largest market for sunitinib malate (for pancreatic cancer) primarily due to the higher number of patients suffering from pancreatic cancer in the country. However, the market in the U.K. is expected to witness a higher growth rate during the forecast period.
The quantitative data in the forecasting model covers various level of analysis, such as epidemiology studies (overall pancreatic cancer incidence and five-year survival), number of drug-treated patients suffering from pancreatic cancer, number of drug-treated patients suffering from pancreatic neuroendocrine tumor (pNET), percentage of patients eligible for taking sunitinib malate, and pricing analysis of sunitinib malate in all G7 countries.
The market research data, current market size, and forecast provided in this report will help key players as well as new entrants to make necessary decisions regarding product offerings, changes in marketing approaches, and R&D investments for innovation in products. This report also provides qualitative assessment of pancreatic cancer, its stages, and approved drugs for pNET.
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market. Analysis provided in the report will help these firms to stay competitive in the market and take strategic decisions on pipeline drugs for pancreatic cancer. Companies purchasing this report can use the below-mentioned information for strategy development, market penetration, and product development/innovation.
The report provides insights on the following pointers: